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Background: Accumulating evidence suggests that dysregulated snoRNA may play a role in the development of
malignancy. In the present study, we investigated the role of SNORD78 in the tumorigenesis of non-small cell lung
cancer (NSCLC).
Methods: We determined the expression level of SNORD78 in NSCLC tissues with quantitative real-time PCR and then
studied its clinical significance. We explored the biological significance of SNORD78 with gain-and-loss-of-function
analyses both in vitro and in vivo.
Results: A great upregulation of SNORD78 was observed in cancer tissues compared to their adjacent normal
tissues. Meanwhile, patients with high SNORD78 expression have significantly poorer prognosis than those with
low expression. Inhibition of SNORD78 suppressed the proliferation of NSCLC cells via inducing G0/G1 cell cycle
arrest and apoptosis while SNORD78 overexpression promoted the cell proliferation. SNORD78 promoted invasion of
NSCLC cells via inducing epithelial-mesenchymal-transition (EMT). SNORD78 was also obviously upregulated in
cancer stem-like cells and is required for the self-renewal of NSCLC. The oncogenic activity of SNORD78 was also
confirmed with in vivo data.
Conclusion: Our study identified that SNORD78 may be a potential therapeutic target for NSCLC.
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Lung cancer represents the most frequent cause of
cancer-related mortality [1]. Non-small cell lung cancer
(NSCLC), including adenocarcinoma and squamous cell
carcinoma, accounts for about 85 % of all lung cancers [2].
Most of NSCLC patients are diagnosed at advanced stages
due to the fact that they are usually asymptomatic at early
stages [3]. In spite of the recent advances in the manage-
ment of NSCLC, the prognosis of NSCLC remains rela-
tively poor [4]. Therefore, it is of urgent need to identify
novel biomarker of NSCLC and reveal the precise molecu-
lar mechanism of the development of NSCLC.* Correspondence: zhengdiok@aliyun.com; chestpathology@126.com
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noncoding RNAs (ncRNAs), including microRNAs (miR-
NAs), long noncoding RNAs (lncRNAs) and small nucleolar
RNAs (snoRNAs), play an important role in the pathogen-
esis of NSCLC [5–7]. Small nucleolar RNAs are a group of
molecules range between 60–300 nucleotides (nt) in length
and represent one of the best characterized groups of
ncRNAs [8]. They are prominently found in the nucleolus
and functions to guide RNAs for post-transcriptional modi-
fication of ribosomal RNAs and some spliceosomal RNAs
[9]. From a structural basis, snoRNAs fall into two categor-
ies termed box C/D snoRNAs (SNORDs) and box H/ACA
snoRNAs (SNORAs) [9, 10]. SNORDs define the target sites
for 2’‑O-ribose methylation of rRNAs or snRNAs, whereas
SNORAs define the target sites for the isomerization of uri-
dine residues into pseudouridine [10]. A growing volume of
literature has indicated that dysregulated snoRNA may play
a role in the development of malignancy. For example, Meiticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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lung cancer. SNORD33, SNORD66, SNORD73B, SNOR
D76, SNORD78, and SNORA42 could be potential bio-
marker of non-small-cell lung cancer [11]. SNORD113-1
functions as a tumor suppressor role in hepatocellular car-
cinoma [9].
A growing volume of work has proposed that the
cancer cell population are heterogeneous, and that a
relatively small subpopulation of cancer cells often
termed “cancer stem-like cells” (CSCs) or “tumor-initiat-
ing cells” harbored enhanced therapy resistance and
brisk tumorigenicity [12, 13]. As a result, CSCs are re-
sponsible for tumor propagation, resistance to conven-
tional therapy, and tumor recurrence [14]. Mannoor
et al. [15] profiled snoRNA expression in cancer stem
cells of lung cancer and found that several snoRNAs
were significantly upregulated in tumor-initiating cells of
lung cancer. We found that snoRD78 was consistently
reported to be upregulated in lung cancer [11] and
tumor-initiating cells of lung cancer [15], suggesting that
SNORD78 might play a role in lung tumorigenesis.
However, the role of SNORD78 in cancer is elusive
and few studies have examined its molecular mechanism
in NSCLC. In this study, we would like to explore the
role of SNORD78 in NSCLC.
Materials and methods
Cell culture
Three NSCLC adenocarcinoma cell lines (A549, SPC-
A1, NCI-H1975), a NSCLC squamous carcinomas cell
line (SK-MES-1), and a normal human bronchial epithe-
lial cell line (16HBE) were purchased from the Institute of
Biochemistry and Cell Biology of the Chinese Academy of
Sciences (Shanghai, China) and were authenticated. The
cell lines were cultured in DMEM or RPMI 1640 (Gibco
BRL), containing 10 % fetal bovine serum (FBS, HyClone)
as well as 100 U/ml penicillin and 100 μg/ml streptomycin
(Invitrogen). Cells were maintained in a humidified incu-
bator at 37 °C in the presence of 5 % CO2. All cell lines
have been passaged for fewer than 6 months.
Patient and clinical samples
The human specimens in this study were sanctioned by
the local ethics committee of Pulmonary Hospital at
Tongji University (Shanghai, China). A total of 56 pri-
mary cancer tissues and paired adjacent noncancerous
tissues (>5 cm from tumor) were obtained from patients
who underwent surgery at Pulmonary Hospital between
2008 and 2011 and were diagnosed with NSCLC (stage
II, III, and IV) based on histopathological evaluation.
These tissues were flash frozen in liquid nitrogen imme-
diately after surgery and subsequently stored at −80 °C
prior to RNA isolation and qRT-PCR analysis. No pa-
tients received anticancer treatments before surgery inthis study. Complete clinicopathological data of the pa-
tients from which the specimens were collected were
available. Overall survival (OS) was defined as the inter-
val between the dates of surgery and death.
RNA extraction and quantitative real-time PCR
Total RNA was isolated from tumor tissues and pur-
chased cell lines using TRIzol (Life Technologies) ac-
cording to supplier’s instructions. RNA concentration
was measured with a NanoDrop ND-2000 spectropho-
tometer (Life Technologies). Reverse transcription was
performed with random primers using the First Strand
cDNA synthesis kit (Takara, Otsu, Shiga, Japan) accord-
ing to the manufacturer’s instructions. The quantitative
real-time polymerase chain reaction (qRT-PCR) was per-
formed using the SYBR Select Master Mix (Applied Bio-
systems, cat: 4472908) on ABI 7500 system (Applied
Biosystems, CA, USA) according to the manufacturer’s
instructions. β-actin was measured as an internal con-
trol. The relative expression fold change of mRNAs was
calculated by the 2−ΔΔCt method. After the reverse tran-
scription, 0.5 μl of the complementary DNA was used
for subsequent qRT-PCR reaction. The primer sequences







For cell expression and tumor samples, each sample
was run in triplicate. qRT-PCR results were analyzed
and expressed relative to CT (threshold cycle) values,
and then converted to fold changes.
Plasmid, shRNA and cell transfection
Small interfering RNAs targeting GAS5 were bought
from Genepharm Technologies (Shanghai, China). Ex-
pression vectors encoding SNORD78 were purchased
from Fulen Gen Company (Guangzhou China). For stable
knockdown of SNORD78, NSCLC cells were trans-
fected with lentiviral constructs encoding two different
SNORD78 shRNAs or nontargeting shRNAs in the
presence of polybrene (8 mg/mL). After 48 h, transduced
cells were grown in culture media containing 1 mg/mL
puromycin for two weeks. The shRNA sequences were as
the followings: shRNA1: GTTGATCAAATGTCTGACCTG,
shRNA2: GACCTGAAATGAGCATGTAGA. For construc-
tion of lentiviral vector expressing human SNORD78 gene,
SNORD78 cDNA was amplificated by PCR with the
primers (forward, 5’-ggggtaccGTGTAATGAT-3’, and re-
verse, 5’-ccgctcgagTGTAGACAAAGGTA-3’). To obtain
cell lines stably expressing SNORD78, A549 cells were in-
fected with the LV-SNORD78 and LV-control viruses. The
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time PCR and named as A549 LV-SNORD78 clone 1 and
LV-SNORD78 clone2.
All transfected cells were selected with puromycin
(1 mg/ml) for two weeks.
Cancer cell invasion assay
Cancer cell invasion assay was performed using Boyden
chambers with filter inserts (pore size, 8.0 μm, Millipore,
MA) coated with Matrigel (40 μl, Sigma, USA) in 24-well
dishes (Corning). Briefly, 1−2 × 105 cells after transfected
with SNORD78 shRNA or control shRNA, LV-SNORD78
or LV-control were seeded in the upper chamber, while
the culture medium (Invitrogen) with 10 % FBS was
placed in the lower chamber. The plates were incubated
for 24 h or 48 h. The cells on the upper surface were
scraped and washed away, whereas the cells on the
lower surface were fixed in 4 % formaldehyde and
stained with 0.05 % crystal violet for 2 h. Finally, cells
were counted under a microscope and the relative
number was calculated. Experiments were independ-
ently repeated in triplicate.
Cell viability assay
Cell viability was assessed by the Cell Counting Kit 8
(CCK-8, Donjindo). Briefly, control and treated A549
and H1975 cells were seeded into 96-well plates at an
initial density of 3000 and 5000 cells/well. At each time
points, 10 μl of CCK-8 solution was added to each well
and incubated for 2 h. The absorbance was measured
by scanning with a microplate reader at 450 nm. Data
were expressed as the percentage of viable cells as
follows: relative viability (%) = (A450treated−A450blank)/
(A450control - A450blank) × 100 %.
Cell cycle analysis
Cells transiently transfected with desired vector were
harvested 48 h after transfection. The cells were washed
for three times by cold PBS, and then cells were fixed in
70 % ethanol in PBS at −20 °C for 24 h. After fixation,
cells were washed with cold PBS and stained with 0.5 ml
of propidium iodide (PI) staining buffer, which contains
200 mg/ml RNase A, 50 μg/ml PI, at 37 °C for 30 min at
4 °C in the dark. The cell-cycle profiles were assayed at
488 nm on an EPICS 752 flow cytometer (Coulter, Hialeah,
FL) equipped with MPLUS software (Phoenix 140 Flow
Systems, San Diego, CA). Data were expressed as percent-
age distribution of cells in G0/G1, S and G2/M phases of
the cell cycle.
Western blot analysis
The harvested cells were centrifuged at 2,000 rpm for
5 min. The total cellular proteins were prepared using RIPA
cell lysis buffer (Cell Signaling Technology) supplementedwith protease inhibitors. The lysates were then col-
lected and subjected to ultrasonication and centrifuga-
tion. The supernatants were collected, and protein
content was determined by Bradford assay. Equal
amounts (30–50 μg) of proteins were applied to an 8–
12 % SDS-polyacrylamide separating gel and trans-
ferred to a PVDF Immobilon-P membrane (Millipore).
The membrane was blocked with 5 % nonfat milk in
TBST and then probed with indicated primary anti-
bodies with gentle shaking at 4 °C overnight. The mem-
branes were washed with TBST (3 × 10 min), incubated
in secondary antibodies at room temperature for 1 h.
Antibody-bound proteins were detected by BeyoECL
Plus kit.
The primary antibodies used in these experiments in-
clude E-cadherin (1:1000) (Abcam), N-cadherin (1:1000)
(Abcam), Vimentin (1:500) (Abcam), p21 (1:1000), p16
(1:1000) and caspase-3 (1:1000). HRP-conjugated goat
anti-rabbit IgG antibody (Abcam) was used as the sec-
ondary antibody.Immunofluorescence analysis
Cells transfected with desired vector were cultured and
fixed on 12 × 12 mm glass slides. For membrane staining
(E-cadherin), cells were fixed with cold 100 % methanol
for 10 min. For intracellular staining (Vimentin, N-
cadherin), the cells were fixed with 4 % (wt/vol) parafor-
maldehyde in PBS and permeabilized by incubation with
0.5 % Triton X−100 in PBS for 2 min. The cells were in-
cubated with 5 % bovine serum albumin in PBS for
20 min at room temperature. After washing with PBS,
the cells were incubated with specific primary antibody
at 4 °C overnight. Antibody dilutions of 1:400 were used
for E-cadherin (Abcam), N-cadherin (Abcam) and
Vimentin (Cell Signaling Technology). The cells were
then washed and incubated with Alexa Fluor 488-
conjugated goat anti-rabbit IgG for 1 h. The nuclei were
stained with 4,6-diamidino-2-phenylindole (DAPI). Sec-
tions were visualized by a LEICA DMI 3000B fluores-
cence microscope with an original magnification × 200.Mammosphere-formation assay
Single cells were plated in ultralow-attachment six-well
plate (Corning) at a density of 10,000 viable cells/mL.
Cells were grown in a serum-free DMEM/F12 medium
(Invitrogen), supplemented with 20 ng/mL EGF and
20 ng/mL bFGF (BD Biosciences). Bovine pituitary ex-
tract was excluded. Fresh medium were added 0.5 ml/
well every three days. Mammospheres >50 μm in diam-
eter were counted at day 8. Images were taken with a
LEICA DMI 3000B with original magnification × 100
or × 400.
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The methylation status of the E-cadherin promoter re-
gion was determined by methylation-specific PCR (MSP)
using bisulfite-modified DNA. Genomic DNA was ex-
tracted using the QIAamp DNA mini kit (Axygen). Two
primer sets were used to amplify the promoter region of
the E-cadherin that incorporated a number of CpG sites,
one specific for the methylated sequence (E-cadherin-M,
forward: 5’-TATGAGTTGTAAGCGGTAGAGTTC-3’; re-
verse: 5’-TACGAACTTAACGAAAAAAAATCAT-3’) and
the other for the unmethylated sequence (E-cadherin-U,
forward: 5’- GAATATGAGTTGTAAGTG GTAGAGTT
T-3’; reverse: 5’-TACAAACTTAACAAAAAAAAATCA
TACT-3’). The primers used in the present study detect
specifically the promoter sequence of the E-cadherin. M
and U are the PCR products of methylated and unmethy-
lated alleles, respectively. The polymerase chain reactions
for E-cadherin-M and E-cadherin-U were carried out in a
50 μl volume containing 1× polymerase chain reaction
buffer (15 mmol/l MgCl2), 2.5 mmol/l mixture of dNTPs,
10 pMof each primer, 4 U HotStart Taq DNApolymerase
(Qiagen, Frankfurt, Germany), and 25 ng to 50 ng of bisul-
fitemodified DNA. Amplification was performed in a ther-
mocycler with the following conditions: 94 °C for 3 min,Fig. 1 SNORD78 is transcribed independently of GAS5. (a) Schematic diagr
exons and SNORD78 resides in intron 7–8 of GAS5. SNORD78 is depicted a
used for RT-PCR are shown. Orientation of arrows indicates the direction o
between the expression of the SNORD78 and GAS5 was not observed. ΔCt va
β-actin expression levels. (c) Expression of GAS5 was decreased, and SNOR
different siRNAs against GAS5. Statistical differences were analyzed relativecycled at 94 °C for 15 s, 60 °C or 57 °C for 15 s, and 72 °C
for 15 s (35 cycles), followed by an extension at 72 °C for
7 min. Methylation-specific PCR experiments were per-
formed at least in duplicate.Animal experiments
Briefly, male BALB/cathymic nude mice (4–6 weeks old)
were obtained from the experimental animal center of
Shanghai Institute for Biological Science. To evaluate
the effect of SNORD78 in nude mice, we constructed
NSCLC H1975 cells with SNORD78 stable down expres-
sion. All mice were injected subcutaneously into either
side of flank area with 1 × 107 SNORD78 stablely down-
regulated or control H1975 cells to establish the NSCLC
xenograft model. Tumor volumes were measured (0.5 ×
length × width2) in mice on a weekly basis. After 6 weeks,
mice were sacrificed, and tumors were exercised and
subjected to immunohistochemical analysis of Ki67. All
animal experiments were performed in animal laboratory
center of Pulmonary Hospital and in accordance with
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
publication no. 85–23, revised 1996). The study protocolam of SNORD78 and its location in GAS5. GAS5 (top) consists of 12
s the gray box. The location of the forward (F) and reverse (R) primers
f the transcription or amplification reaction. (b) Linear correlation
lues were used to measure gene expression, which was normalized by
D78 was not significantly changed in A549 and SPC-A1 cells with two
to siRNA control. *, p< 0.05
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Pulmonary Hospital.
Statistical analysis
All statistical analyses were performed with SPSS version
19.0 software (SPSS software, Armonk, NY, USA). All
data were presented as mean ± standard deviation from
three independent experiments with each measured inFig. 2 SNORD78 expression in NSCLC cell lines, cancer tissues and its clinical sig
lines (A549, SK-MES-1, SPC-A1 and NCI-H1975) compared with the normal bron
SNORD78 between non-small cell lung cancer tissues and matched non-tumor
statistical differences between samples were analyzed with paired samples t-tes
levels of SNORD78 between adenocarcinoma tissues and squamous cell carcino
statistical differences between samples were analyzed with paired samples t-test
lung parenchyma. Positive mainly nuclear expression of SNORD78 in repr
(magnification × 400) (e) Patients with high levels of SNORD78 expression
low levels of SNORD78 expression (p =0.0113, log-rank test). *, p < 0.05; **, p <
the means (95 % CI)triplicate. The gene expression level of SNORD78 in tu-
mors was compared with adjacent normal tissues utiliz-
ing the paired sample t-test, whereas the association
between SNORD78 expression and clinical characteris-
tics was evaluated using the chi-square test. Survival
curves were plotted by the Kaplan-Meier method, and
the long-rank comparison was carried out to assess dif-
ferences between stratified survival groups using thenificance. (a) qRT-PCR analysis of SNORD78 expression levels in NSCLC cell
chial epithelial cell line (16HBE). (b) Difference in expression levels of
NSCLC tissues. The expression of SNORD78 was normalized to β-actin. The
t (n = 56, p < 0.0001). (c) There were no significant differences in expression
ma tissues. The expression of SNORD78 was normalized to β-actin. The
(p = 0.9577). (d) Negative staining of SNORD78 in adjacent non-neoplasmic
esentative cases of squamous cell carcinoma and adenocarcinoma.
showed reduced overall survival times compared with patients with
0.01. (f) Multivariate analysis of HRs for OS is shown. HRs are presented as




Clinicopathologic parameters High Low Number of cases p value
Age (years) 10 14 24 0.2301
≤60 14 18 32
>60
Gender
Male 13 11 24 0.4043
Female 13 19 32
Diameter
≤3 11 9 20 0.024a
>3 24 12 36
Lymph node metastasis
Yes 21 9 30 0.0004a
No 13 13 26
TNM stage
I–II 5 16 21 0.0354a
III 25 10 35
Degree of differentiation
Well and moderately 14 16 30 0.3778
Poorly 15 11 26
aStatistically significant (p < 0.05)
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analysis was performed to calculate the hazard ratio
(HR) and the 95 % confidence interval (CI) to evaluate
the association between SNORD78 expression and sur-
vival. Cox regression analysis was used to determine the
independent factors, which were based on the variables
selected by univariate analysis. The expression differ-
ences between cell lines, the expression changes after
transfection, cell viability and cell invasion assays were
analyzed using independent samples t-test.Table 2 Univariate and multivariate analysis of factors associated wi
Univariate analys
Risk factors HR (95 % CI)
Age (≤60/>60) 2.899 (0.997–8.42
Gender(male/female) 3.618 (0.948–13.8
Diameter(≥3/<3) 3.125 (1.093–8.92
Lymph node metastasis(Yes/No) 3.703 (1.119–11.5
TNM stage (III/I–II) 4.689 (1.633–14.5
SNORD78 expression(high/low) 5.495 (1.678–17.8
Histological grade (poorly/well and moderately) 1.666 (0.652–4.25
aStatistically significant (p < 0.05)Results
Characterization of SNORD78 in NSCLC
SNORD78 is located in 1q25, one of most frequently
amplified chromosomal segments in solid tumors, par-
ticularly NSCLC [16–18]. Furthermore, we performed a
computational screen and found that SNORD78 resides
in intron 7–8 of GAS5 (Fig. 1a). To explore the potential
relationship between the SNORD78 and GAS5 transcripts,
we first examined the expression levels of SNORD78 and
GAS5 in 15 NSCLC tissues. The results showed that no
correlation (r = −0.080, p = 0.776) existed between the
transcriptional levels of SNORD78 and GAS5 (Fig. 1b).
Furthermore, SNORD78 was statistically unchanged in
A549 and SPC-A1 cells transfected with two different
short interfering (siRNAs) (designated as si-1 and si-2)
against GAS5, despite significant reduction in GAS5 mes-
senger RNA expression (Fig. 1c).SNORD78 was upregulated in NSCLC
SNORD78 was reported to be upregulated in lung can-
cer tissues [11]. To further corroborate the previous
finding of Liao et al. [11], we firstly detected SNORD78
expression in a series of lung cancer cell lines including
adenocarcinoma and squamous carcinoma subtypes util-
izing qRT-PCR. When normalized to normal bronchial
epithelial cell line (16HBE), the RNA level of SNORD78
was increased in the NSCLC cancer cell lines (A549, SK-
MES-1, SPC-A1, NCI-H1975) by 2.7- to 5.8-fold com-
pared with 16HBE (Fig. 2a).
We detected SNORD78 expression in 56 pairs of
NSCLC tissues and in their adjacent normal tissues util-
izing qRT-PCR. The data showed that SNORD78 expres-
sion was obviously increased, and the average intensity
was increased 3-fold in tumorous than in adjacent nor-
mal tissues (Fig. 2b). The average ΔCt expression value
of SNORD78 was 6.75 in NSCLC tissues, ranking from
5.91 to 8.32, when compared with β-actin. Furthermore,
there were no statistical differences of expression of
SNORD78 between adenocarcinoma and squamous cellth overall surivival in NSCLC patients (56 pairs)
is Multivariate analysis
p value HR (95 % CI) p value
6) 0.063
12) 0.06
9) 0.035a 2.036 (1.472–3.651) 0.011a
07) 0.014a 2.491 (1.233–3.932) 0.015a
06) 0.030a 2.675 (1.512–4.367) 0.001a
57) 0.005a 1.933(1.401–3.212) 0.007a
9) 0.408
Fig. 3 Effect of SNORD78 knockdown on NSCLC cell viability, cell cycle and apoptosis. (a) qRT-PCR analysis of SNORD78 expression following
treatment of H1975 cells with two specific shRNAs targeting SNORD78. (b) H1975 cells were transfected with SNORD78 shRNAs or shRNA control.
CCK8 assays were performed to determine the proliferation of H1975 cells. (c) Cell cycle analysis determined the relative cell numbers in each
cell-cycle phase after propidium iodide staining of SNORD78-downregulated H1975 cells. Numbers inside bars represent percentages of cells in
each phase. Data represent the mean ± S.D. from three independent experiments. (d) H1975 cells, treated as described in Fig. 3a, were collected
for western blotting analysis of the G0/G1 arrest markers, p16 and p21. Relative protein expression was identified (n = 3). (e) Annexin V/PI staining
and flow cytometry analysis assessing apoptosis in H1975 cells after SNORD78 shRNAs transfection. Data represent the mean ± S.D. from three
independent experiments. (f) Changes in pro-apoptotic factor caspase-3 activation and Bax/Bcl-2 ratio were shown by western blotting analysis
and normalized to β-actin after SNORD78 shRNAs transfection. Data represent the mean ± S.D. from three independent experiments. *, p < 0.05;
**, p < 0.01
Zheng et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:49 Page 7 of 15
Zheng et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:49 Page 8 of 15carcinoma, suggesting that SNORD78 was shared in two
major histological types of NSCLC (Fig. 2c). In situ
hybridization (ISH) studies confirmed the upregulation
of SNORD78 in NSCLC (Fig. 2d).
The association between SNORD78, clinicopathological
characteristics and prognosis after surgery
The patients with NSCLC were then stratified according
to SNORD78 expression level (median split) and com-
pared for different clinicopathologic features (age, sex,
tumor size, lymph node status, distant metastasis, and sur-
vival time). Results revealed that SNORD78 expression
was positively correlated with the TNM stage (p = 0.0354,
p < 0.05), lymph node metastasis (p =0.0004, p < 0.05) and
tumor size (p =0.024, p < 0.05). There was no significant
correlation between SNORD78 expression with age, gen-
der, or degree of differentiation (Table 1).
Kaplan-Meier survival analysis and log-rank tests using
patient postoperative survival were conducted to further
evaluate the correlation between SNORD78 and prognosis
of patients with NSCLC. The cumulative survival rate
was significantly better in patients with lower-SNORD78-Fig. 4 Effect of SNORD78 overexpression on NSCLC cell viability and cell cy
of A549 cells with SNORD78. (b) A549 cells were transfected with SNORD78
of A549 cells. (c) Cell cycle analysis determined the relative cell numbers in
overexpressed A549 cells. Numbers inside bars represent percentages of ce
transfection of A549 cells with SNORD78. Data represent the mean ± S.D. frexpressing tumours than in those with higher- SNORD78-
expressing tumors (p = 0.0113, HR (95 % CI) = 1.933
(1.401-3.212)); Fig. 2d). In addition, the univariate analysis
revealed that the tumor size, lymph node metastasis,
TNM stage and SNORD78 expression were significantly
correlated with overall survival (Table 2). The multivari-
ate analysis demonstrated that tumor size (p = 0.011),
lymph node metastasis (p = 0.015), TNM stage (p =
0.001) and SNORD78 expression (p = 0.007) were in-
dependent risk factors for overall survival (Fig. 2e)
(Table 2).
SNORD78 is required for efficient proliferation of NSCLC
cells
The fact that SNORD78 is frequently upregulated in pri-
mary NSCLC tissues and NSCLC cells prompted us to
explore the role of SNORD78 dysregulation in NSCLC
cells. We constructed cell lines that stably downregu-
lated SNORD78 by lentivirus infection of H1975 cells
with specific shRNAs (Fig. 3a), which expressed rela-
tively higher level of SNORD78. The CCK-8-based assay
detected significant decrease in the proliferation ofcle. (a) qRT-PCR analysis of SNORD78 expression following transfection
or control. CCK8 assays were performed to determine the proliferation
each cell-cycle phase after propidium iodide staining of SNORD78
lls in each phase. (d) qRT-PCR analysis of GAS5 expression following
om three independent experiments. *, p < 0.05; **, p < 0.01
Fig. 5 (See legend on next page.)
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Fig. 5 SNORD78 promoted invasion of NSCLC cells via inducing epithelial-mesenchymal-transition (EMT). (a) H1975 cells were transfected with shRNA
control or shRNA SNORD78. Transwell assays were performed to investigate the invasive ability of H1975 cells. Data represent the mean ± S.D. from three
independent experiments. (b) A549 cells were transfected with LV-control or LV-SNORD78. Transwell assays were performed to investigate the invasive
ability of A549 cells. Data represent the mean ± S.D. from three independent experiments. *, p< 0.05; **, p< 0.01. (c) immunofluorescence images of H1975
cells stained using antibodies against E-cadherin, Vimentin or N-cadherin after transfected with shRNA control or SNORD78 shRNA-2 (original
magnification × 200). (d) Western-blot analysis of phenotypic markers after SNORD78 knockdown in H1975 cells. Relative protein expression was
identified (n = 3) and normalized to β-actin. Data represent the mean ± S.D.. (e) Results of MSP analysis of E-cadherin gene in SNORD78
shRNA-2-transfected H1975 cells, and control cells. M and U, PCR products of methylated and unmethylated alleles, respectively
Zheng et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:49 Page 10 of 15H1975 cells after knockdown of SNORD78 (Fig. 3b).
Thus, we evaluated the effect of SNORD78 expression
on cell cycle distribution and cell apoptosis in H1975
cells by flow cytometry. We found that SNORD78 silen-
cing induced a significant G0/G1 arrest (Fig. 3c). Further-
more, the western blot analysis indicated that knockdown
of SNORD78 significantly increased the expression of G0/
G1 arrest markers, p16 and p21 (Fig. 3d). These data dem-
onstrated that SNORD78 silencing induced H1975 cell
cycling arrest at the G0/G1 phase. Flow cytometry assay
indicated that suppression of SNORD78 induced the in-
crease of cell apoptosis by phycoerythrin (PE)-conjugated
Annexin V staining and FACS (Fig. 3e). To explore the
underlying mechanism of SNORD78’s role in cell apop-
tosis, we determined the expression of pro-apoptotic fac-
tor, Bax, Bcl and caspase-3 by western blot. SNORD78
knockdown increased the expression levels of cleaved
caspase-3 and Bax/Bcl-2 ratio (Fig. 3f). These results dem-
onstrated that SNORD78 knockdown may inhibit the pro-
liferation of NSCLC cells through inducing cell G0/G1
arrest and apoptosis.
To confirm the effect of ectopic expression of SNORD78
on cell proliferation, we overexpressed SNORD78 by
lentivirus infection (Fig. 4a). The results showed that
the overexpression of SNORD78 increased proliferation
of NSCLC cancer cell in vitro (Fig. 4b,c). To exclude
the possibility that biological effects of SNORD78 de-
pend on its regulation of GAS5, we determined the ex-
pression level of GAS5 with SNORD78 overexpression.
We found that overexpression of SNORD78 had no sig-
nificant effects on the expression level of GAS5 (Fig. 4d).
These finding suggest that SNORD78 may take a part in
the development of NSCLC.
SNORD78 promoted invasion of NSCLC cells via inducing
epithelial-mesenchymal-transition (EMT)
Transwell assay revealed a substantial decrease in the
number of cells that penetrated the porous filter with
SNORD78 knockdown, suggesting impaired invasion
ability of H1975 cells (Fig. 5a). Meanwhile, a significant
increase in cancer cell invasion was observed in NSCLC
cells A549 in vitro with SNORD78 overexpression (Fig. 5b).
These data suggest that SNORD78 promoted the invasion
of NSCLC cells. Invasion is an important characteristic ofNSCLC and emerging evidence has linked invasion with
EMT. The epithelial-mesenchymal-transition (EMT) is a
well-coordinated process that occurs during embryonic de-
velopment and a pathological feature in tumorigenesis [19,
20]. During such a process, the epithelial phenotype cells
lose the expression of E-cadherin and other components of
cell to cell junctions and adopt a mesenchymal phenotype
[21]. The EMT process has been shown to play a vital role
in cancer invasion, metastasis, expansion of the population
of cancer stem cells and therapeutic resistance [21]. We
then examined the effect of SNORD78 on the EMT
process of NSCLC cells.
Compared with the vector-transfected cells, H1975 cells
became more round-shaped and came up with an epithe-
lial phenotype with SNORD78 knockdown (Fig. 5c). With
the immunofluorescence analysis, inhibition of SNORD78
in H1975 cells resulted in an obvious upregulation in the
expression of epithelial marker E-cadherin and a great re-
duction in the expression of mesenchymal markers N-
cadherin and Vimentin (Fig. 5c). The western blot analysis
confirmed the results from the immunofluorescence ana-
lysis (Fig. 5d). Together, it indicates that SNORD78 pro-
moted the EMT process and thus, SNORD78 might play a
role in the development of NSCLC.
As SNORDs are known to define the target sites for
2’‑O-ribose methylation of rRNAs or snRNAs, we ex-
plored whether DNA methylation contributes to the
EMT process with Methylation-Specific PCR to examine
the role of methylation in deregulation of E-cadherin.
We found that the promoter regions of E-cadherin
gene from control H1975 cells were strongly methyl-
ated, whereas the SNORD78 silenced H1975 cells had
unmethylated E-cadherin promoter region (Fig. 5e).
These results indicate that aberrant methylation of E-
cadherin gene promoter by SNORD78 may contribute
to the EMT process in NSCLC.
SNORD78 is required for the self-renewal of cancer-stem
cells of NSCLC
Mannoor et al. [15] profiling results revealed SNORD78
was upregulated in cancer-stem cells of NSCLC. We
used CD133+ and CD133−cells that were isolated from
A549 cells (Fig. 6a) and confirmed that SNORD78 was
specifically upregulated in cancer-stem cells (Fig. 6b).
Fig. 6 (See legend on next page.)
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Fig. 6 SNORD78 is required for the self-renewal of cancer-stem cells of NSCLC. (a) CD133 positive cells were isolated from NSCLC cells A549. (b) There
was a high level of expression of SNORD78 in CD133+ cells versus CD133- cells of A549 cells as determined by qPCR analysis. (c) Representative
images of mammospheres formed from A549 cells. Inhibition of SNORD78 reduced the number of mammospheres (original magnification × 100).
(d) Smaller sizes of mammospheres were observed after SNORD78 knockdown in comparison with control (original magnification × 400). Representative
images of mammospheres were shown above. Experiments were independently repeated at least three times. (e) Western-blot analysis of stemness
factors after SNORD78 knockdown in H1975 cells. Relative protein expression was identified (n = 3) and normalized to β-actin. Data represent
the mean ± S.D..*, p < 0.05; **, p < 0.01
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fewer (Fig. 6c) and smaller mammospheres (Fig. 6d)
compared with vector-transfected cells, implying that
SNORD78 is required for the self-renewal of cancer-stem
cells of NSCLC. Furthermore, inhibition of SNORD78 re-
sulted in the downregulation of a series of stemness fac-
tors, which has been shown to play an important in the
self-renewal of cancer stem-like cells in NSCLC [22, 23].
SNORD78 knockdown inhibits in vivo tumorigenesis of
NSCLC cells
To validate the effect of SNORD78 on NSCLC cell tumori-
genesis in vivo, H1975-shRNA-SNORD78 or H1975-
shRNA-control cells were injected into flanks of nude
mice. Palpable tumors formed with 1 week. Tumor vol-
ume was measured on a weekly basis. Four weeks after
injection, the average tumor volume of H1975 cells trans-
fected with shRNA-SNORD78 was 1.35 ± 0.34 cm3, whichFig. 7 The effects of SNORD78 on in vivo tumor growth of NSCLC. Inhibition
mouse models of H1975 cells. Tumor growth curves (a) and tumor volumes (
(c) H&E and immunohistochemical staining demonstrated that suppression o
indicated by the expression of Ki67-positive and caspase-3-positive cells. *, p <was significantly lower than tumors in the control group
(2.51 ± 0.48 cm3, p < 0.01; Fig. 7a,b). Immunohistochemi-
cal staining of tumor tissues indicated a decrease in ki67
and an increase in cleaved caspase-3 in shRNA-SNORD78
vs. shRNA-control (Fig. 7c). The in vivo data complement
the in vitro studies of SNORD78 and confirm the onco-
genic activity of SNORD78 in NSCLC.
Predictive value of SNORD78
Previous reports presented that both miRNA and
lncRNA can act as biomarkers for predicting progression
and prognosis. In this study, we were curious about the
translation of SNORD in clinical life. Therefore, we fur-
ther determined the predictive potency of SNORD78 as
a biomarker for metastasis. Receiver operating character-
istics (ROC) curve was used to evaluate the predictive
efficacy of SNORD78. For lymph node metastasis,
SNORD78 alone showed low-predictive efficiency sinceof SNORD78 suppressed tumor growth in subcutaneous implantation
b) of subcutaneous implantation models of gallbladder cancer are shown.
f SNORD78 inhibited the aggressive phenotype of NSCLC cells in vivo, as
0.05; **, p < 0.01
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0.372–0.740, p = 0.291, Fig. 8). Next, we explored whether
serum tumor biomarkers could improve the predictive
efficiency of SNORD78. Among the serum biomarkers an-
alyzed (CEA, AFP, CA125, CA19-9, and NSE), the com-
bination of SNORD78 and CEA significantly improved the
predictive efficiency (AUC = 0.642, 95 % CI 0.484–0.791,
p = 0.029, Fig. 8).
Discussion
NSCLC is one the most frequent causes of cancer-
related motility. The understanding of NSCLC pathogen-
esis has improved through the identification of activating
mutations in and amplifications of oncogenes, including
KRAS [24], EGFR [25], KARS [26], and inactivating muta-
tions in tumor suppressive genes, such as p53 [27, 28].
However, the mechanism of NSCLC development remains
largely unknown. A growing volume of literature has indi-
cated the role of small nucleolar RNAs in cancer [7, 9, 11].
snoRNA U50 has been demonstrated to act as a tumor-
suppressor in cancer [29, 30]. Mei et al. [7] reported that a
diverse number of snoRNAs are differentially expressed in
lung cancer with respect to the corresponding matched
tissue. Mannoor et al. [15] profiled snoRNA expression in
cancer stem cells of lung cancer and found that a num-
ber of snoRNAs were significantly upregulated in tumor-Fig. 8 SNORD78 might be a biomarker in NSCLC. Expression of SNORD78 w
analysis was used for merged SNORD78 and CEA to predict tumor metastainitiating cells of lung cancer. SNORD78 was consistently
reported to be upregulated in lung cancer [11] and tumor-
initiating cells of lung cancer [15], suggesting that
SNORD78 might play a role in lung tumorigenesis.
In the present study, we confirmed that the expression
of SNORD78 was obviously upregulated in NSCLC
tissues compared with adjacent normal tissues and in
cancer stem-like cells of NSCLC compared to their non-
stem counterparts. Furthermore, SNORD78 was shared
in two major histological types of NSCLC. SNORD78
expression was positively correlated with the TNM stage,
lymph node metastasis and tumor size. High expression
of SNORD78 was also associated with poor prognosis of
NSCLC.
We then determine in vitro functional significance of
SNORD78 in lung cancer cell lines through gain- and loss-
of-function analyses. We demonstrated that SNORD78 is
required for efficient proliferation and invasion of NSCLC
cells. Our data revealed that SNORD78 silencing inhibited
cell proliferation via inducing a significant G0/G1 arrest
and cell apoptosis. The proliferation-promoting effect of
SNORD78 was confirmed with SNORD78 overexpression
in A549 cells. SNORD78 silencing suppressed cell invasion
via reversing the epithelial-mesenchymal-transition of
NSCLC. The concept of cancer stem-like cells or tumor-
initiating cells have proposed that the heterogeneous tumoras detected in subgroups grouped by metastasis. Further ROC curve
sis in NSCLC
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properties such as self-renewal, multiplex differentiation,
chemo- and radio-resistance, high tumorigenicity, and they
may play pivotal parts in the development, progression, me-
tastasis, recurrence and multidrug resistance of cancer [12,
13]. The identification of molecules that play a role in the
self-renewal of cancer stem-like cells may provide a key
standpoint for better understanding tumorigenesis and de-
veloping prognostic biomarkers and targeted therapy. As
SNORD78 is indeed upregulated in cancer stem-like cells
of NSCLC, we knocked down SNORD78 in cancer stem-
like cells of lung cancer and found that shRNA-SNORD78
transfected cells formed fewer and smaller mammo-
spheres compared with vector-transfected cells, implying
that SNORD78 is important for the self-renewal of cancer
stem-like cells of NSCLC. Inhibition of SNORD78 re-
sulted in the downregulation of a series of stemness fac-
tors, such as Sox2 and Oct4, which has been shown to
enhance NSCLC malignancy by inducing cancer stem
cell-like properties and epithelial-mesenchymal-transition
[25, 26]. The in vivo data complement the in vitro studies
of SNORD78 and confirm the oncogenic activity of
SNORD78 in NSCLC.
In conclusion, we demonstrate that the expression of
SNORD78 was significantly upregulated in NSCLC tis-
sues. We also showed that SNORD78 promoted the pro-
liferation and invasion of NSCLC cells and is vital for
the self-renewal of cancer stem-like cells, suggesting that
SNORD78 may play a functional role in NSCLC devel-
opment. Our study may add our understanding to the
molecular mechanisms through which SNORD78 con-
tributes to the tumor progression, which may facilitate
the development of snoRNA-directed diagnostics and
therapeutics against cancers.
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